First Horizon Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

First Horizon Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-272	Closed	-$27.7K	–	2536
2023 Q2	$27.7K	Hold	272	–	–	﹤0.01%	1144
2023 Q1	$24.7K	Sell	272 -114	-30%	-$6.69K	﹤0.01%	1181
2022 Q4	$14.7K	Buy	+386	New	+$13.3K	﹤0.01%	1384

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

First Horizon Advisors's RETA Position: Q3 2023 in Review

First Horizon Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 272 shares — an estimated $27.7K sold.

First Horizon Advisors first reported a position in RETA in Q4 2022 and held it in 3 quarters. The position peaked at $27.7K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

First Horizon Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
First Horizon Advisors sold 272 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $27.7K.
First Horizon Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 3 quarters.
First Horizon Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $27.7K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on First Horizon Advisors's 13F filing for Q3 2023, filed 27 Oct 2023.